Desloratadine

How to order Desloratadine

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Desloratadine on Prescriptsy

Desloratadine is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Desloratadine is a second-generation, non-sedating antihistamine used to treat the symptoms of allergic rhinitis and chronic idiopathic urticaria in adults and children aged one year and over.

As the principal active metabolite of loratadine, desloratadine provides targeted histamine H1 receptor blockade without requiring hepatic activation, offering reliable 24-hour symptom control with a single daily dose.

It is one of the most widely used allergy treatments in the United Kingdom, available both on NHS prescription and as a pharmacy medicine from community pharmacies.

Allergic conditions are extremely common in the UK.

Allergic rhinitis affects approximately 20 to 30% of the adult population and a similar proportion of children, with seasonal hay fever being the most familiar form.

Chronic idiopathic urticaria, characterised by recurring itchy wheals without an identifiable external trigger, affects around 1% of the population and can persist for months or years.

Both conditions significantly impair quality of life, affecting sleep, concentration, work productivity, and emotional wellbeing.

This page provides a thorough clinical overview of desloratadine, explaining how it works, who it is suitable for, how to take it, expected outcomes, side effects, safety precautions, and practical guidance for obtaining treatment in the UK.

Important safety information about desloratadine

Before reading further, note the following key safety points.

• Desloratadine is generally well tolerated and is classified as a non-sedating antihistamine. However, a small number of patients may experience mild drowsiness.
• Do not take desloratadine if you are allergic to desloratadine, loratadine, or any of the other ingredients listed in the patient information leaflet.
• Use with caution if you have severe kidney disease or a history of seizures.
• Seek immediate medical attention (call 999) if you experience signs of a severe allergic reaction such as swelling of the face, tongue, or throat, difficulty breathing, or collapse.
• Consult your GP before taking desloratadine if you are pregnant or breastfeeding.

Understanding allergic rhinitis and urticaria

Allergic rhinitis occurs when the immune system overreacts to airborne allergens such as pollen, house dust mites, pet dander, or mould spores.

Exposure triggers mast cells in the nasal mucosa to release histamine and other inflammatory mediators, producing the characteristic symptoms of sneezing, nasal itching, rhinorrhoea (runny nose), nasal congestion, and itchy, watery eyes.

Seasonal allergic rhinitis (hay fever) is driven primarily by grass pollen in the UK, peaking between May and July, though tree pollen (February to May) and weed pollen (June to September) also contribute.

Perennial allergic rhinitis persists year-round and is typically triggered by indoor allergens.

Chronic idiopathic urticaria is defined as the spontaneous appearance of wheals (raised, itchy, pale or red swellings on the skin), angioedema, or both, occurring on most days for six weeks or longer without a clearly identifiable external cause.

In many cases, the underlying mechanism involves autoimmune activation of mast cells.

The itching and visible skin changes can be profoundly distressing and are frequently underestimated by those who do not experience the condition.

Both allergic rhinitis and chronic urticaria are driven primarily by histamine acting on H1 receptors. This makes antihistamines the cornerstone of pharmacological treatment for both conditions.

How desloratadine works: mechanism of action

Desloratadine is a selective, long-acting antagonist of the peripheral histamine H1 receptor.

By binding to and blocking H1 receptors on vascular endothelium, smooth muscle cells, and sensory nerve endings, desloratadine prevents histamine from triggering its characteristic allergic effects: vasodilation, increased vascular permeability (leading to oedema and wheals), smooth muscle contraction, mucus secretion, and stimulation of itch-sensing nerve fibres.

Beyond simple receptor blockade, desloratadine demonstrates additional anti-allergic and anti-inflammatory properties.

In vitro studies have shown that it inhibits the release of pro-inflammatory cytokines (including interleukin-4, interleukin-6, and interleukin-13), reduces expression of adhesion molecules on vascular endothelium, and suppresses chemotaxis of eosinophils.

These broader anti-inflammatory actions may contribute to its clinical effectiveness, particularly in conditions such as chronic urticaria where inflammation extends beyond simple histamine release.

Crucially, desloratadine has very low affinity for muscarinic cholinergic receptors, alpha-adrenergic receptors, and serotonin receptors.

This selectivity explains why it causes significantly less sedation, dry mouth, and urinary retention than first-generation antihistamines such as chlorphenamine and promethazine.

Desloratadine also does not readily cross the blood-brain barrier at therapeutic doses, further reducing central nervous system effects.

Clinical evidence and UK guidelines

Desloratadine has been extensively studied in large, randomised, placebo-controlled trials involving thousands of patients with seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Studies consistently demonstrate significant reductions in total symptom scores for sneezing, rhinorrhoea, nasal itching, and ocular symptoms compared with placebo, with improvement typically evident within 1 to 3 hours of the first dose.

In chronic idiopathic urticaria, clinical trials have shown that desloratadine 5 mg daily significantly reduces pruritus (itching) intensity, wheal number, and wheal size compared with placebo, with sustained benefit over treatment periods of six weeks and longer.

NICE Clinical Knowledge Summaries and BSACI (British Society for Allergy and Clinical Immunology) guidelines recommend second-generation antihistamines as first-line treatment for both allergic rhinitis and urticaria, with desloratadine specifically listed as a suitable option.

The BSACI guideline on the management of chronic urticaria notes that if the standard dose of a second-generation antihistamine is insufficient, the dose may be increased up to fourfold (off-label) before considering alternative treatments.

This step-up approach should be undertaken under specialist guidance.

Pharmacokinetics and dosing rationale

Desloratadine is well absorbed after oral administration. Food does not significantly affect the extent of absorption, although it may delay peak plasma concentration by approximately one hour.

Peak plasma levels are reached in approximately 3 hours.

The elimination half-life is approximately 27 hours, supporting effective 24-hour symptom control with once-daily dosing and allowing some flexibility in dosing time without loss of efficacy.

Desloratadine undergoes extensive hepatic metabolism, primarily via CYP3A4 and UGT (uridine glucuronosyltransferase) enzymes, to form 3-hydroxydesloratadine, which is subsequently glucuronidated and excreted.

Unlike its parent compound loratadine, desloratadine does not require cytochrome P450-mediated activation, which reduces its susceptibility to drug interactions affecting hepatic enzymes.

Dosage and administration

The recommended dose for adults and adolescents aged 12 years and over is 5 mg (one tablet) once daily, taken with or without food at approximately the same time each day. Tablets should be swallowed whole with water.

For children aged 6 to 11 years, the recommended dose is 2.5 mg once daily, available as an oral solution or orodispersible (dispersible) tablet.

Children aged 1 to 5 years may be prescribed 1.25 mg once daily as an oral solution.

The oral solution is particularly useful for young children who cannot swallow tablets. Desloratadine is not recommended for children under 1 year of age due to insufficient data.

No dose adjustment is required for elderly patients. In patients with severe renal impairment, desloratadine should be used with caution, as clearance may be reduced.

There is no specific dose recommendation for hepatic impairment, but caution is warranted in severe liver disease.

For seasonal allergic rhinitis, desloratadine may be taken throughout the relevant pollen season and discontinued when exposure ends.

For perennial allergic rhinitis and chronic urticaria, continuous treatment may be needed for extended periods, with periodic review by your GP to assess ongoing necessity.

Side effects of desloratadine

Common side effects

In clinical trials, desloratadine was well tolerated with an adverse event profile similar to placebo.

The most frequently reported side effects in adults include headache, dry mouth, and fatigue. In children, diarrhoea, pyrexia (fever), and insomnia were reported more frequently than in adults.

These side effects are generally mild and transient.

Uncommon and rare side effects

Uncommon effects include dizziness, drowsiness (somnolence), tachycardia (increased heart rate), palpitations, abdominal pain, nausea, vomiting, dyspepsia, elevated liver enzymes, and rash.

Rare post-marketing reports include anaphylaxis, angioedema, hepatitis, psychomotor hyperactivity, seizures, hallucinations, and QT interval prolongation. Very rare severe skin reactions such as erythema multiforme have also been reported.

When to seek medical advice

Seek emergency medical attention (call 999 or attend A&E) if you experience swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, widespread skin blistering, or signs of an anaphylactic reaction.

Contact your GP or NHS 111 if you notice persistent dizziness, palpitations, jaundice, or any symptoms that concern you.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Renal and hepatic impairment

Patients with severe renal impairment should use desloratadine with caution, as reduced clearance may lead to higher plasma levels. Liver disease may similarly affect metabolism.

If you have significant kidney or liver problems, inform your prescriber so that appropriate monitoring or an alternative antihistamine can be considered.

Epilepsy and seizure risk

Although seizures are extremely rare with desloratadine, patients with a history of epilepsy or conditions that lower the seizure threshold should use this medicine with caution. Inform your prescriber if you have a seizure history.

Pregnancy and breastfeeding

There is limited data on desloratadine use during pregnancy.

Animal studies have not shown direct harmful effects on the foetus, but as a precautionary measure, desloratadine should be avoided during pregnancy unless the clinical benefit is considered to outweigh the potential risk.

Desloratadine is excreted in breast milk at concentrations similar to plasma levels.

The prescriber should weigh the benefits of continued breastfeeding and treatment against the potential risk to the infant.

Driving and operating machinery

At the recommended dose, desloratadine does not generally impair psychomotor performance. However, individual responses vary.

If you experience drowsiness or dizziness, do not drive or operate machinery until the effect resolves.

Be particularly cautious when starting treatment or when combining desloratadine with other medicines or alcohol.

Drug interactions

Desloratadine has a low interaction potential.

In formal interaction studies, co-administration with ketoconazole, erythromycin, azithromycin, fluoxetine, and cimetidine increased desloratadine plasma levels but did not produce clinically significant adverse effects or ECG changes.

No dose adjustment is typically required. However, as a general precaution, inform your doctor or pharmacist of all medicines, supplements, and herbal products you are taking.

Desloratadine compared with other antihistamines

The UK market offers several second-generation antihistamines, including cetirizine, loratadine, fexofenadine, and bilastine. All are effective for allergic rhinitis and urticaria, but they differ in pharmacological properties.

Cetirizine has slightly greater sedative potential than desloratadine or fexofenadine.

Loratadine requires hepatic conversion to desloratadine for full activity, making its effectiveness more variable in patients with impaired liver function or those taking enzyme-inhibiting medicines.

Fexofenadine, like desloratadine, is a non-sedating active metabolite. The choice between agents is often guided by individual patient response, tolerability, and cost.

How to get desloratadine in the UK

Desloratadine is available in the UK in several ways.

Certain branded and generic formulations are classified as pharmacy (P) medicines and can be purchased from community pharmacies without a prescription, following a brief consultation with the pharmacist.

This route is suitable for adults and adolescents seeking short-term or seasonal relief.

For children requiring specific paediatric formulations, for chronic urticaria, or for patients who prefer NHS supply, your GP can prescribe desloratadine.

The standard NHS prescription charge in England is currently 9.90 pounds per item. Prescriptions are free in Scotland, Wales, and Northern Ireland.

Patients in England who use multiple regular prescriptions may save money by purchasing a prepayment certificate.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) can also issue prescriptions for desloratadine following an appropriate clinical assessment.

Practical tips for managing allergies

Alongside antihistamine treatment, allergen avoidance measures can help reduce symptom burden.

For hay fever, monitor pollen forecasts (available from the Met Office), keep windows closed during high pollen periods, shower and change clothes after outdoor exposure, and use wraparound sunglasses to protect your eyes.

For perennial rhinitis triggered by house dust mites, consider allergen-proof mattress and pillow covers, regular vacuuming with a HEPA filter, and reducing soft furnishings in bedrooms.

For chronic urticaria, keeping a symptom diary may help identify patterns or potential triggers, although in many cases no external trigger is found. Wearing loose, cool clothing and avoiding hot baths may reduce flare frequency.

When to seek further medical advice

Contact your GP or NHS 111 if your symptoms do not improve within a few days of starting desloratadine, if you develop new or worsening symptoms, or if you have questions about long-term use.

Seek emergency care (call 999 or attend A&E) if you develop signs of a severe allergic reaction including throat swelling, breathing difficulty, or anaphylaxis.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Desloratadine 5 mg Tablets, Summary of Product Characteristics (EMC)
• Desloratadine, British National Formulary (BNF)
• NICE CKS: Allergic rhinitis
• NICE CKS: Urticaria
• Hay fever, NHS
• Hives (urticaria), NHS
• MHRA Yellow Card Scheme